Phase II Study of Oxaliplatin and Taxotere in Metastatic Bladder Cancer
Phase 2
Completed
- Conditions
- Bladder Cancer
- Registration Number
- NCT00186277
- Lead Sponsor
- Stanford University
- Brief Summary
To combine oxaliplatin and taxotere in patients who have had prior cisplatin therapy in bladder cancer.
- Detailed Description
To test the combination of oxaliplatin chemotherapy in combination with taxotere chemotherapy in patients with advanced bladder cancer who have failed one prior chemotherapy.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Tolerability of the this combination in patients with recurrent metastatic bladder cancer. 1 year
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Stanford University School of Medicine
🇺🇸Stanford, California, United States
Stanford University School of Medicine🇺🇸Stanford, California, United States